Coldstream Capital Management Inc. Acquires 179 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Coldstream Capital Management Inc. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% in the 4th quarter, Holdings Channel reports. The fund owned 9,884 shares of the medical research company’s stock after buying an additional 179 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $5,142,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Barrett & Company Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $28,000. FPC Investment Advisory Inc. purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $28,000. Pillar Financial Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Missouri Trust & Investment Co bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $29,000. Finally, Endeavor Private Wealth Inc. bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $30,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on TMO. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday. UBS Group lowered their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday. Scotiabank reduced their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research note on Friday. Royal Bank of Canada dropped their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $616.95.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This represents a 25.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares of the company’s stock, valued at $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Down 0.6 %

NYSE TMO opened at $424.02 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock’s fifty day moving average price is $487.28 and its 200-day moving average price is $527.17. The stock has a market cap of $160.06 billion, a P/E ratio of 25.65, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.